## Review setup

- **Input scope** Abstract only
- **Assessment boundary** Claims and evidence as presented in the abstract
- **Shared manuscript claim summary** The authors propose that Aloe vera extract suppresses breast cancer cell growth in vitro and in vivo, and that computational screening identifies DNA-intercalating bioactive compounds, particularly riboflavin, as potential mediators. They further claim that riboflavin shows higher binding affinity to DNA than daunorubicin based on MM/PBSA calculations, and suggest riboflavin warrants further preclinical and clinical testing.
- **Visible evidence base** Abstract text only; no figures, tables, methods details, or supplementary materials provided
- **Missing materials affecting confidence** Full methods, experimental data (cell lines, animal models, dosages, statistical analyses), docking and simulation parameters, MM/PBSA calculation details, compound identification and quantification in Aloe vera extract, and any validation of computational predictions with experimental binding assays

## Reviewer

- **Overall assessment** The abstract presents a plausible hypothesis linking Aloe vera bioactive compounds to DNA intercalation and anti-proliferative activity, but the evidence base is insufficient to establish the central claims. The in vitro and in vivo results are described only qualitatively, and the computational findings lack methodological detail and experimental validation. The conclusion that riboflavin is a lead candidate is not supported by the provided evidence.
- **Who would be interested in the results, and why** Researchers in natural product pharmacology, cancer biology, and computational drug discovery may find the hypothesis interesting. The potential repurposing of dietary compounds as DNA-intercalating agents could appeal to those studying chemoprevention or adjuvant therapies. However, interest would be conditional on stronger evidence.
- **Major strengths** The study addresses a relevant question about the molecular mechanism of Aloe vera's anti-cancer properties. The combination of experimental and computational approaches is conceptually appropriate. The focus on DNA intercalation as a mechanism is specific and testable.
- **Major Concerns** The abstract lacks quantitative experimental data, the computational methods are not described in sufficient detail, and the link between computational predictions and biological activity is not established. The claim that riboflavin outperforms daunorubicin is based solely on MM/PBSA calculations without experimental corroboration.
- **Minor Comments** The abstract would benefit from clearer reporting of experimental conditions and results. The term "lead bioactive compounds" is used without defining the selection criteria. The conclusion is overly speculative given the evidence presented.
- **Technical failings that need to be addressed before the case is established** The absence of experimental validation for the computational predictions, the lack of quantitative in vitro and in vivo data, and the missing methodological details for docking and simulation are critical gaps.
- **Assessment against Nature-style criteria** Originality is moderate; the idea of DNA intercalation by Aloe vera compounds is not entirely novel. Scientific importance is potentially high if validated, but the current evidence does not support broad significance. Interdisciplinary readership is plausible given the combination of biology and computation, but the abstract is too thin to engage specialists. Technical soundness cannot be assessed from the abstract alone. Readability for nonspecialists is acceptable but the lack of context and data limits comprehension.

### Major Concerns

- **Concern ID** R1-M1  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Experimental evidence  
- **Claim pointer** "In-vitro and in-vivo studies confirm that Aloe vera extract effectively suppresses the growth of breast cancer cells without significant cytotoxicity towards non-cancerous normal immortal cells."  
- **Evidence pointer** Abstract, Results section  
- **Concern** The abstract states that in vitro and in vivo studies confirm growth suppression, but provides no quantitative data such as IC50 values, tumor volume measurements, cell viability percentages, or statistical significance. The claim of "without significant cytotoxicity" is not supported by any comparative data.  
- **Why it matters** Without quantitative experimental evidence, the biological relevance and specificity of the observed effects cannot be evaluated. This is a core claim that underpins the entire study.  
- **Resolution test** Provide specific experimental data, including dose-response curves, statistical analyses, and appropriate controls, in the full manuscript.

- **Concern ID** R1-M2  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Computational methodology  
- **Claim pointer** "Computational screening predicts that growth suppression may be due to the presence of DNA intercalating bioactive compounds (riboflavin, daidzin, aloin, etc.) contained in Aloe vera."  
- **Evidence pointer** Abstract, Methods and Results sections  
- **Concern** The abstract does not describe the docking protocol, scoring functions, simulation parameters, or the criteria for identifying "intercalating" compounds. The selection of compounds and the basis for predicting intercalation are not specified.  
- **Why it matters** Reproducibility and validity of computational predictions depend on detailed methodological transparency. Without this, the claim that these compounds are responsible for the observed effects is unverifiable.  
- **Resolution test** Include full details of the docking and simulation procedures, including software versions, force fields, and validation steps, in the methods section.

- **Concern ID** R1-M3  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Claim-evidence alignment  
- **Claim pointer** "MM/PBSA calculation showed that riboflavin has a higher binding affinity at the DNA binding sites compared to standard drug daunorubicin."  
- **Evidence pointer** Abstract, Results section  
- **Concern** The MM/PBSA result is presented as a definitive finding, but no numerical values, error estimates, or comparison context are provided. Moreover, binding affinity from MM/PBSA does not necessarily translate to biological efficacy, and no experimental binding assay is mentioned.  
- **Why it matters** The conclusion that riboflavin is a promising candidate relies heavily on this computational comparison. Without experimental validation, the claim is speculative and could be misleading.  
- **Resolution test** Provide MM/PBSA values with standard deviations, and include experimental validation such as surface plasmon resonance, isothermal titration calorimetry, or a DNA binding assay.

- **Concern ID** R1-M4  
- **Severity** Major  
- **Blocking** Yes  
- **Axis** Compound identification  
- **Claim pointer** "the presence of DNA intercalating bioactive compounds (riboflavin, daidzin, aloin, etc.) contained in Aloe vera"  
- **Evidence pointer** Abstract, Results section  
- **Concern** The abstract implies these compounds are present in Aloe vera extract, but no analytical data (e.g., HPLC, mass spectrometry) are provided to confirm their identity and concentration in the extract used for the biological experiments.  
- **Why it matters** If the compounds are not actually present in the extract at relevant concentrations, the proposed mechanism is invalid. This is a critical link between the experimental and computational components.  
- **Resolution test** Include analytical characterization of the extract, with quantification of the identified compounds.

### Minor Comments

- **Concern ID** R1-m1  
- **Severity** Minor  
- **Axis** Clarity  
- **Affected element** Abstract, Background  
- **Evidence pointer** Abstract, Background section  
- **Issue** The phrase "no detailed molecular mechanism of action studies has been reported" is vague and does not specify the scope of the literature search.  
- **Required correction** Clarify the statement by specifying the type of studies reviewed and the time frame.

- **Concern ID** R1-m2  
- **Severity** Minor  
- **Axis** Terminology  
- **Affected element** Abstract, Conclusions  
- **Evidence pointer** Abstract, Conclusions section  
- **Issue** The term "lead bioactive compounds" is used without defining the criteria for "lead" status.  
- **Required correction** Define the selection criteria for lead compounds, such as binding affinity thresholds or predicted toxicity.

- **Concern ID** R1-m3  
- **Severity** Minor  
- **Axis** Speculation  
- **Affected element** Abstract, Conclusions  
- **Evidence pointer** Abstract, Conclusions section  
- **Issue** The statement that riboflavin "is worthy of testing for the management of cancer" is overly speculative given the lack of experimental validation.  
- **Required correction** Soften the conclusion to reflect the preliminary nature of the findings and the need for further validation.

## Risk / unsupported claims

- The claim that Aloe vera extract suppresses breast cancer growth in vitro and in vivo is unsupported due to lack of quantitative data.
- The claim that specific compounds (riboflavin, daidzin, aloin) are responsible for the observed effects is unsupported without analytical confirmation of their presence in the extract.
- The claim that riboflavin has higher binding affinity than daunorubicin is unsupported without numerical MM/PBSA data and experimental validation.
- The overall conclusion that riboflavin may be exploited as an anti-proliferative agent is not established from the provided evidence.